CompletedNot Applicable

An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding

South Korea4,133 participantsStarted 2019-04-18

Plain-language summary

This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for the prevention of gastrointestinal bleeding.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age≥19
✓. Among patients who visited the hospital due to the onset or recurrence of acute coronary syndrome or cerebral infarction within 1 month prior to registration, patients who are expected to receive DAPT(Clopidogrel + Aspirin) for at least 6 months, in combination with Esomezol Cap for the purpose of preventing gastrointestinal bleeding Patients receiving or planning to receive treatment
✓. Subject who can written informed consent voluntarily

What they're measuring

The incidence of total Major Adverse CardioCerebrovascular Events(MACCE) from baseline

Timeframe: 6 months

Trial details

NCT IDNCT05487560

SponsorHanmi Pharmaceutical Company Limited

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-06-22

View on ClinicalTrials.gov More Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months trials